Article
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2020
Zhao Jun, Lin Gen, Zhuo Minglei, Fan Zaiwen, Miao Liyun, Chen Likun, Zeng Aiping, Yin Rong, Ou Yangming, Shi Zhihui, Yin Jie, Gao Wen, Chen Jianhua, Zhou Xiangdong, Zeng Yong, Liu Xiang, Xu Huamin, Chen Rongrong, Xia Xuefeng, Carbone David P
Abstract excerpt
OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. However, the degree and duration of response to osimertinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.